Inhaled Nano-Treatment targets lung scarring
NCT ID NCT07571291
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This study is testing a new inhaled treatment for pulmonary fibrosis, a condition that causes lung scarring. The treatment uses tiny fat bubbles (liposomes) coated with a special substance to target harmful cells in the lungs. The goal is to reduce inflammation and scarring. The study involves 30 people with pulmonary fibrosis and is currently active but not recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rheumatology unit IRCCS Policlinico San Matteo Pavia
Pavia, 27100, Italy
Conditions
Explore the condition pages connected to this study.